Trial Profile
Steady state telithromycin pharmacokinetics and pharmacodynamic in adult patients with mild-moderate acute exacerbation of chronic obstructive pulmonary disease treated with a standard oral dose 800 mg od for 5 days.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Jul 2011
Price :
$35
*
At a glance
- Drugs Telithromycin (Primary)
- Indications Bacterial infections; Chronic bronchitis; Chronic obstructive pulmonary disease; Respiratory tract infections
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms TELI-AECOPD
- Sponsors Sanofi
- 07 Jul 2011 New trial record